CCR5 promoter region polymorphisms in systemic lupus erythematosus

Abstract This study investigated the impacts of CCR5 promoter region polymorphisms on the development of systemic lupus erythematosus (SLE) by comparing CCR5 genotypes and haplotypes from SLE patients with ethnically matched controls. A total of 382 SLE patients (289 European‐derived and 93 African‐derived) and 375 controls (243 European‐derived and 132 African‐derived) were genotyped for the CCR2‐64I G > A (rs1799864), CCR5‐59353 C > T (rs1799988), CCR5‐59356 C > T (rs41469351), CCR5‐59402 A > G (rs1800023) and CCR5‐59653 C > T (rs1800024) polymorphisms through polymerase chain reaction‐restriction fragment length polymorphism and direct sequencing. Previous data from CCR5Δ32 analysis was included in the study to infer the CCR5 haplotypes and as a possible confounding factor in the binary logistic regression. European‐derived patients showed a higher frequency of CCR5 wild‐type genotype (conversely, a reduced frequency of Δ32 allele) and a reduced frequency of the HHG*2 haplotype compared to controls; both factors significantly affecting disease risk [ p = .003 (OR 3.5, 95%CI 1.6–7.5) and 2.0% vs. 7.2% (residual p = 2.9E − 5), respectively]. Additionally, the HHA/HHB, HHC and HHG*2 haplotype frequencies differed between African‐derived patients and controls [10% vs. 20.5% (residual p = .003), 29.4% vs. 17.4% (residual p = .003) and 3.9% vs. 0.8% (residual p = .023), respectively]. Considering the clinical manifestations of the disease, the CCR5Δ32 presence was confirmed as a susceptibility factor to class IV nephritis in the African‐derived group and when all patients were grouped for comparison [ p corrected = .012 (OR 3.0; 95%CI 3.0–333.3) and p corrected = .0006 (OR 6.8; 95%CI 1.9–24.8), respectively]. In conclusion, this study indicates that CCR5 promoter polymorphisms are important disease modifiers in SLE. Present data reinforces the CCR5Δ32 polymorphism as a protective factor for the development of the disease in European‐derived patients and as a susceptibility factor for class IV nephritis in African‐derived patients. Furthermore, we also described a reduced frequency of HHA/HHB and an increased frequency of HHC and HHG*2 haplotypes in African‐derived patients, which could modify the CCR5 protein expression in specific cell subsets.